Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 175

2.

Effects of ABCB1 rs1045642 polymorphisms on the efficacy and safety of amlodipine therapy in Caucasian patients with stage I-II hypertension.

Sychev D, Shikh N, Morozova T, Grishina E, Ryzhikova K, Malova E.

Pharmgenomics Pers Med. 2018 Sep 20;11:157-165. doi: 10.2147/PGPM.S158401. eCollection 2018.

3.

ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients.

Uruga H, Mino-Kenudson M.

Pharmgenomics Pers Med. 2018 Sep 17;11:147-155. doi: 10.2147/PGPM.S156672. eCollection 2018. Review.

4.

Qualitative user evaluation of a revised pharmacogenetic educational toolkit.

Mills R, Haga SB.

Pharmgenomics Pers Med. 2018 Sep 4;11:139-146. doi: 10.2147/PGPM.S169648. eCollection 2018.

5.

The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty.

Sychev DA, Levanov AN, Shelekhova TV, Bochkov PO, Denisenko NP, Ryzhikova KA, Mirzaev KB, Grishina EA, Gavrilov MA, Ramenskaya GV, Kozlov AV, Bogoslovsky T.

Pharmgenomics Pers Med. 2018 Jul 25;11:127-137. doi: 10.2147/PGPM.S169277. eCollection 2018. Erratum in: Pharmgenomics Pers Med. 2018 Sep 26;11:167.

6.

The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders.

Levchenko A, Losenkov IS, Vyalova NM, Simutkin GG, Bokhan NA, Wilffert B, Loonen AJ, Ivanova SA.

Pharmgenomics Pers Med. 2018 Jul 20;11:121-126. doi: 10.2147/PGPM.S171423. eCollection 2018.

7.

Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder.

Zastrozhin MS, Grishina EA, Denisenko NP, Skryabin VY, Markov DD, Savchenko LM, Bryun EA, Sychev DA.

Pharmgenomics Pers Med. 2018 Jun 29;11:113-119. doi: 10.2147/PGPM.S160763. eCollection 2018.

8.

CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole.

Denisenko NP, Sychev DA, Sizova ZM, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Grishina EA.

Pharmgenomics Pers Med. 2018 Jun 18;11:107-112. doi: 10.2147/PGPM.S159708. eCollection 2018.

9.

Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean population.

Hernandez-Suarez DF, Botton MR, Scott SA, Tomey MI, Garcia MJ, Wiley J, Villablanca PA, Melin K, Lopez-Candales A, Renta JY, Duconge J.

Pharmgenomics Pers Med. 2018 Jun 8;11:95-106. doi: 10.2147/PGPM.S165805. eCollection 2018.

10.

Emerging biomarkers in the diagnosis of prostate cancer.

Filella X, Fernández-Galan E, Fernández Bonifacio R, Foj L.

Pharmgenomics Pers Med. 2018 May 16;11:83-94. doi: 10.2147/PGPM.S136026. eCollection 2018. Review.

11.

Meta-analysis of the association of the haptoglobin genotype with cardiovascular outcomes and the pharmacogenomic interactions with vitamin E supplementation.

Asleh R, Briasoulis A, Berinstein EM, Wiener JB, Palla M, Kushwaha SS, Levy AP.

Pharmgenomics Pers Med. 2018 Apr 23;11:71-82. doi: 10.2147/PGPM.S159454. eCollection 2018.

12.

Budget impact model for oncopharmacogenetics from the perspective of mandatory basic health insurance in Switzerland using the example of breast cancer.

Szucs TD, Szillat KP, Blozik E.

Pharmgenomics Pers Med. 2018 Apr 23;11:67-69. doi: 10.2147/PGPM.S154368. eCollection 2018.

13.

H3Africa: current perspectives.

Mulder N, Abimiku A, Adebamowo SN, de Vries J, Matimba A, Olowoyo P, Ramsay M, Skelton M, Stein DJ.

Pharmgenomics Pers Med. 2018 Apr 10;11:59-66. doi: 10.2147/PGPM.S141546. eCollection 2018. Review.

14.

CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment.

Silvado CE, Terra VC, Twardowschy CA.

Pharmgenomics Pers Med. 2018 Mar 29;11:51-58. doi: 10.2147/PGPM.S108113. eCollection 2018. Review.

15.

Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke.

Kryukov AV, Sychev DA, Andreev DA, Ryzhikova KA, Grishina EA, Ryabova AV, Loskutnikov MA, Smirnov VV, Konova OD, Matsneva IA, Bochkov PO.

Pharmgenomics Pers Med. 2018 Mar 22;11:43-49. doi: 10.2147/PGPM.S157111. eCollection 2018.

16.

The utility of pharmacogenetic testing to support the treatment of bipolar disorder.

Ielmini M, Poloni N, Caselli I, Espadaler J, Tuson M, Grecchi A, Callegari C.

Pharmgenomics Pers Med. 2018 Mar 16;11:35-42. doi: 10.2147/PGPM.S160967. eCollection 2018.

17.

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment.

Chen L, Prasad GVR.

Pharmgenomics Pers Med. 2018 Mar 7;11:23-33. doi: 10.2147/PGPM.S107710. eCollection 2018. Review.

18.

Which attributes of whole genome sequencing tests are most important to the general population? Results from a German preference study.

Plöthner M, Schmidt K, Schips C, Damm K.

Pharmgenomics Pers Med. 2018 Feb 14;11:7-21. doi: 10.2147/PGPM.S149803. eCollection 2018.

19.

The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction.

Zastrozhin MS, Grishina EA, Ryzhikova KA, Smirnov VV, Savchenko LM, Bryun EA, Sychev DA.

Pharmgenomics Pers Med. 2017 Dec 28;11:1-5. doi: 10.2147/PGPM.S144503. eCollection 2018.

20.

Ethiopian health care professionals' knowledge, attitude, and interests toward pharmacogenomics.

Abdela OA, Bhagavathula AS, Gebreyohannes EA, Tegegn HG.

Pharmgenomics Pers Med. 2017 Dec 5;10:279-285. doi: 10.2147/PGPM.S145336. eCollection 2017.

Supplemental Content

Loading ...
Support Center